

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-2 (Cancelled)

Claim 3 (Withdrawn)

Claim 4 (Currently Amended): ~~The use of a GABA_B receptor antagonist for the treatment of~~ A method for increasing neurotrophin levels in the in the central nervous system (CNS) of a patient with Parkinson's disease, amyotrophic lateral sclerosis and, stress-induced neurodegeneration, said method comprising administering to the patient an amount of a GABA_B receptor antagonist sufficient to increase neurotrophin levels in the CNS of the patient.

Claim 5 (Withdrawn)

Claims 6-10 (Cancelled)

Claim 11 (Withdrawn)

Claims 12 (Cancelled)

Claim 13 (Withdrawn)

Claims 14 (Cancelled)

Claim 15 (Withdrawn)

Claims 16 (Cancelled)

Claim 17 (New): A method for increasing neurotrophin levels in the central nervous system (CNS) of a patient with Parkinson's disease, comprising administering to the patient an amount of a GABA_B receptor antagonist sufficient to increase neurotrophin levels in the CNS of a patient with Parkinson's disease.

Claim 18 (New): A method for treating Parkinson's disease, comprising administering to the patient in need of such treatment a therapeutically effective amount of a GABA_B receptor antagonist.

Claim 19 (New): The method of claim 17 wherein the antagonist is administered daily.

Claim 20 (New): The method of claim 18 wherein the antagonist is administered daily.

Claim 21 (New): The method of claim 4 wherein the GABA_B receptor antagonist is selected from the group consisting of 3-{1(S)-[3-(cyclohexylmethyl)hydroxyphosphinyl]-2(S)-hydroxy-propylamino]ethyl}benzoic acid; 3-{1(R)-[3-(cyclohexylmethyl)hydroxyphosphinyl-2(S)-hydroxy-propylamino]ethyl}benzoic acid; and 3-aminopropyl-(n-butyl)-phosphinic acid.

Claim 22 (New): The method of claim 17 wherein the GABA_B receptor antagonist is selected from the group consisting of 3-{1(S)-[3-(cyclohexylmethyl)hydroxyphosphinyl]-2(S)-hydroxy-propylamino]ethyl}benzoic acid; 3-{1(R)-[3-(cyclohexylmethyl)hydroxyphosphinyl-2(S)-hydroxy-propylamino]ethyl}benzoic acid; and 3-aminopropyl-(n-butyl)-phosphinic acid.

Claims 23 (New): The method of claim 18 wherein the GABA_B receptor antagonist is selected from the group consisting of 3-{1(S)-[3-(cyclohexylmethyl)hydroxyphosphinyl]-2(S)-hydroxy-propylamino]ethyl}benzoic acid; 3-{1(R)-[3-(cyclohexylmethyl)hydroxyphosphinyl-2(S)-hydroxy-propylamino]ethyl}benzoic acid; and 3-aminopropyl-(n-butyl)-phosphinic acid.

Claim 24 (New): The method of Claim 4 where the GABA_B receptor antagonist is administered to a patient with Parkinson's disease or amyotrophic lateral sclerosis.

Claim 25 (New): The method of Claim 23 where the GABA_B receptor antagonist is administered to a patient with Parkinson's disease.